$1.5158
Insights on Lava Therapeutics Nv
Revenue is down for the last 2 quarters, 5.13M → 53.0K (in $), with an average decrease of 99.0% per quarter
Netprofit is up for the last 3 quarters, -14.99M → -8.83M (in $), with an average increase of 30.9% per quarter
In the last 1 year, Seagen, Inc. has given 76.2% return, outperforming this stock by 153.7%
2.57%
Downside
Day's Volatility :2.57%
Upside
0.0%
25.66%
Downside
52 Weeks Volatility :84.69%
Upside
79.4%
Period | Lava Therapeutics Nv | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -14.84% | -1.7% | 0.0% |
6 Months | -20.22% | 2.1% | 0.0% |
1 Year | -77.54% | -5.8% | -6.0% |
3 Years | -89.4% | 18.7% | -3.7% |
Market Capitalization | 39.7M |
Book Value | $2.08 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -1.92 |
Wall Street Target Price | 6.8 |
Profit Margin | 0.0% |
Operating Margin TTM | -20239.62% |
Return On Assets TTM | -23.62% |
Return On Equity TTM | -68.44% |
Revenue TTM | 9.1M |
Revenue Per Share TTM | 0.34 |
Quarterly Revenue Growth YOY | -99.7% |
Gross Profit TTM | -20.7M |
EBITDA | -48.7M |
Diluted Eps TTM | -1.92 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.8 |
EPS Estimate Next Year | -1.79 |
EPS Estimate Current Quarter | -0.49 |
EPS Estimate Next Quarter | -0.17 |
What analysts predicted
Upside of 348.61%
Sell
Neutral
Buy
Lava Therapeutics Nv is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Lava Therapeutics Nv | 28.46% | -20.22% | -77.54% | -89.4% | -89.4% |
![]() Moderna, Inc. | 1.97% | -39.54% | -57.19% | -44.9% | 317.74% |
![]() Regeneron Pharmaceuticals, Inc. | 4.11% | 12.67% | 8.22% | 60.25% | 115.31% |
![]() Novo Nordisk A/s | 4.26% | 28.93% | 61.48% | 201.7% | 342.4% |
![]() Seagen, Inc. | -0.54% | 9.52% | 76.18% | 20.18% | 233.4% |
![]() Vertex Pharmaceuticals Incorporated | -3.93% | 9.64% | 10.62% | 54.06% | 92.15% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Lava Therapeutics Nv | 0.25 | NA | NA | -1.8 | -0.68 | -0.24 | 0.0 | 2.08 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -11.52 | -0.22 | -0.07 | 0.0 | 35.32 |
![]() Regeneron Pharmaceuticals, Inc. | 22.78 | 22.78 | 9.01 | 42.5 | 0.17 | 0.09 | 0.01 | 234.47 |
![]() Novo Nordisk A/s | 43.04 | 43.04 | 2.03 | 2.62 | 0.89 | 0.22 | 0.01 | 20.77 |
![]() Seagen, Inc. | NA | NA | 18.53 | -4.16 | -0.28 | -0.13 | 0.03 | 13.52 |
![]() Vertex Pharmaceuticals Incorporated | 26.52 | 26.52 | 0.41 | 15.04 | 0.23 | 0.14 | 0.02 | 64.05 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Lava Therapeutics Nv | Buy | $39.7M | -89.4% | 0.25 | 0.0% |
![]() Moderna, Inc. | Buy | $29.6B | 317.74% | 24.73 | -38.0% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $87.0B | 115.31% | 22.78 | 30.47% |
![]() Novo Nordisk A/s | Buy | $470.4B | 342.4% | 43.04 | 35.11% |
![]() Seagen, Inc. | Hold | $40.0B | 233.4% | NA | -32.61% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $91.0B | 92.15% | 26.52 | 35.94% |
Organization | Lava Therapeutics Nv |
Employees | 69 |
CEO | Mr. Stephen Allen Hurly M.B.A., M.Sc. |
Industry | Healthcare |